Edition:
India

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

5.12HKD
6 Aug 2020
Change (% chg)

HK$0.03 (+0.59%)
Prev Close
HK$5.09
Open
HK$5.08
Day's High
HK$5.16
Day's Low
HK$5.00
Volume
8,905,699
Avg. Vol
22,914,587
52-wk High
HK$6.88
52-wk Low
HK$3.50

Latest Key Developments (Source: Significant Developments)

Luye Pharma Group Gets Acceptance For Clinical Trial Application Of LPM4870108 Tablets
Tuesday, 23 Jun 2020 

June 23 (Reuters) - Luye Pharma Group Ltd <2186.HK>::CLINICAL TRIAL APPLICATION OF LPM4870108 TABLETS ACCEPTED BY CENTRE FOR DRUG EVALUATION OF PRC.  Full Article

Luye Pharma Group Says IND Application Of LY03013 Accepted By CDE In China
Thursday, 18 Jun 2020 

June 18 (Reuters) - Luye Pharma Group Ltd <2186.HK>::IND APPLICATION OF RIVASTIGMINE MULTI-DAY TRANSDERMAL PATCH (LY03013) ACCEPTED BY CDE IN CHINA.  Full Article

Luye Pharma Group Says Clinical Trial Application Of Injection Accepted
Thursday, 11 Jun 2020 

June 11 (Reuters) - Luye Pharma Group Ltd <2186.HK>::CLINICAL TRIAL APPLICATION OF HYDROCHLORIDE IRINOTECAN FLOXURUDINELIPOSOME INJECTION ACCEPTED BY CENTRE FOR DRUG EVALUATION.  Full Article

Luye Pharma Group Gets Approval For Initiating Clinical Trial For Denosumab Injection In U.S.
Tuesday, 9 Jun 2020 

June 9 (Reuters) - Luye Pharma Group Ltd <2186.HK>::RECOMBINANT ANTI-RANKL FULLY HUMAN MONOCLONAL ANTIBODY INJECTION GOT APPROVAL FROM U.S. FDA TO INITIATE CLINICAL TRIALS.  Full Article

Luye Pharma Group Says Unit Signed An Exclusive Distribution And Marketing Agreement With Alvogen Korea
Wednesday, 20 May 2020 

May 20 (Reuters) - Luye Pharma Group Ltd <2186.HK>::UNIT SIGNED AN EXCLUSIVE DISTRIBUTION AND MARKETING AGREEMENT WITH ALVOGEN KOREA.AGREEMENT FOR SEROQUEL® AND SEROQUEL XR ® IN SOUTH KOREA.  Full Article

Luye Pharma Group Gets Approval For Clinical Trial For Ly03014 In China
Tuesday, 31 Mar 2020 

March 31 (Reuters) - Luye Pharma Group Ltd <2186.HK>::GETS APPROVAL FOR CLINICAL TRIAL FOR LY03014 IN CHINA.GROUP'S CLASS 1 NEW DRUG LPM3480392 INJECTION HAS OBTAINED APPROVAL FROM CENTRE FOR DRUG EVALUATION TO INITIATE CLINICAL TRIALS.  Full Article

Luye Pharma Posts FY Profit Attributable RMB1,468.6 MLN, Up 12.7%
Friday, 27 Mar 2020 

March 27 (Reuters) - Luye Pharma Group Ltd <2186.HK>::FY PROFIT ATTRIBUTABLE RMB1,468.6 MILLION, UP 12.7%.FY REVENUE INCREASED 22.9% TO RMB6,357.6 MILLION.PROPOSED A FINAL DIVIDEND OF RMB0.054 PER SHARE.  Full Article

Luye Pharma Group Says Lpm3480392 Injection Product Received Formal Acceptance
Monday, 9 Mar 2020 

March 9 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LPM3480392 INJECTION PRODUCT RECEIVED FORMAL ACCEPTANCE FROM CENTRE FOR DRUG EVALUATION OF PRC.  Full Article

Luye Pharma Group Now Pursuing Acquisition Of 98.0% Of Stake In Shandong Boan
Monday, 17 Feb 2020 

Feb 17 (Reuters) - Luye Pharma Group Ltd <2186.HK>::NOW PURSUING ACQUISITION OF 98.0% OF EQUITY INTEREST IN SHANDONG BOAN.  Full Article

Luye Pharma Says Unit Signed Exclusive Distribution & Marketing Service Agreement With Cipla Medpro South Africa
Monday, 10 Feb 2020 

Feb 10 (Reuters) - Luye Pharma Group Ltd <2186.HK>::UNIT SIGNED EXCLUSIVE DISTRIBUTION AND MARKETING SERVICE AGREEMENT WITH CIPLA MEDPRO SOUTH AFRICA (PTY) LTD.UNDER DEAL, CIPLA MEDPRO GETS EXCLUSIVE DISTRIBUTION & MARKETING RIGHTS IN SOUTH AFRICA, NAMIBIA AND BOTSWANA FOR SEROQUEL.  Full Article

BRIEF-Luye Pharma Group Says Clinical Trial Application Of Lurbinected Accepted By CDE Of PRC

* CLINICAL TRIAL APPLICATION OF LURBINECTEDIN FOR INJECTION (LY01017) ACCEPTED BY CENTRE FOR DRUG EVALUATION OF PRC Source text for Eikon: Further company coverage: